At a glance
- Originator Sanofi-Synthelabo
- Class Antihypertensives; Propanolamines
- Mechanism of Action Alpha adrenergic receptor antagonists; Beta-adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
Most Recent Events
- 30 Aug 1999 No development reported for Hypertension in France (IV)